Cancer Immunotherapy Trials Not Immune from Imprecise Selection of Patients
Mené sur 423 patients atteints d'un cancer du poumon non à petites cellules exprimant PD-L1 de stade IV ou récidivant, cet essai de phase III compare l'efficacité, du point de vue de la survie sans progression, et la toxicité du nivolumab et d'une chimiothérapie à base de sels de platine
Arguably, no drug class has more radically and rapidly altered the management of non–small-cell lung cancer (NSCLC) than inhibitors of the interaction between programmed death 1 (PD-1) and its ligand PD-L1. By impeding this negative regulatory signal for T-cell response, PD-1 and PD-L1 inhibitors result in longer survival than does chemotherapy among patients with previously treated NSCLC.1–4 In this issue of the Journal, Carbone and colleagues report on a trial that compared the PD-1 inhibitor nivolumab with chemotherapy as first-line treatment for advanced NSCLC in a population of patients selected on the basis of PD-L1 expression level.5 Progression-free survival (...)
New England Journal of Medicine , éditorial, 2016